Jason Harris


Obesity Linked With Higher Distress in Breast and Prostate Cancers

October 07, 2019

Obese patients being treated for breast or prostate cancer showed higher levels of mental and physical distress than nonobese patients with these diseases, but the pattern did not hold true in those with colorectal cancer, according to a study.

Cancer Researchers Win Nobel Prize

October 02, 2018

Immunotherapy pioneers James P. Allison and Dr. Tasuku Honjo have won the 2018 Nobel Prize in Physiology or Medicine for their research that eventually led to the use of immune checkpoint inhibitors to treat cancer.

Xtandi Granted Priority Review for Prostate Cancer Treatment

March 20, 2018

The Food and Drug Administration granted Xtandi (enzalutamide) a priority review to a supplemental new drug application for the treatment of patients with nonmetastatic castration-resistant prostate cancer, according to the companies developing the drug, Pfizer and Astellas.

FDA Grants Lorlatinib a Priority Review for Lung Cancer Treatment

February 13, 2018

Lorlatinib was granted a priority review to a new drug application (NDA) for patients with ALK-positive metastatic non–small cell lung cancer (NSCLC) who have progressed on one or more ALK tyrosine kinases inhibitors (TKIs).

Keytruda Gets Priority Review for Lymphoma Subset

December 11, 2017

Keytruda (pembrolizumab) was granted a priority review to a supplemental biologics license application (sBLA) to be used to treat adult and pediatric patients with relapsed or refractory primary mediastinal large B-cell lymphoma (PMBCL).

Oropharyngeal Cancer Risks Include Number of Sexual Partners, Smoking

December 09, 2017

The incidence of human papillomavirus-related oropharyngeal cancer (HPV-OPC) is on the rise. Researchers at Johns Hopkins University assessed survey data to determine whether the risk among the general population is rising as well. Results show that for most people, the risk remains low.

Kisqali Extends Progression-Free Survival for Premenopausal Breast Cancer Subsets

December 07, 2017

New research demonstrates that a CDK4/6 inhibitor, used in combination with standard endocrine therapy with temporary ovarian suppression significantly improves progression-free survival in younger patients who currently have few treatment options.

Drug Granted Breakthrough Status to Treat Relapsed or Refractory Myeloma

November 03, 2017

A new drug, GSK2857916, was granted a breakthrough therapy designation by the FDA to treat patients who have relapsed or refractory multiple myeloma, according to GlaxoSmithKline (GSK), the manufacturer of the agent.

Approval Sought for Avastin in the Frontline Ovarian Cancer Setting

October 30, 2017

If approved, the new indication would make frontline Avastin available in combination with carboplatin and paclitaxel, followed by Avastin alone, for women with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer. The FDA is expected to render a decision on the sBLA by June 25, 2018.

Higher-Dose, Less Frequent Kyprolis Benefits Patients With Myeloma

October 25, 2017

Once weekly Kyprolis (carfilzomib) had better efficacy than lower-doses of the drug given twice a week to treat patients with relapsed/refractory multiple myeloma, according to results from the phase 3 ARROW trial.

Drug Combination Granted FDA Breakthrough Designation for Melanoma Treatment

October 23, 2017

The combination of Tafinlar (dabrafenib) and Mekinist (trametinib) was granted a breakthrough therapy designation by the Food and Drug Administration (FDA) for the adjuvant treatment of patients who have stage 3 melanoma and a BRAF V600 mutation, after they have already had a complete resection.

Opdivo Granted Priority Review for Post-Surgical Melanoma Treatment

October 18, 2017

Opdivo (nivolumab) was granted a priority review to a supplemental biologics license application (sBLA) to treat patients with melanoma who have a high risk of disease recurrence after complete surgical resection, according to Bristol-Myers Squibb (BMS), the company that makes the drug.

Cabometyx Improves Survival in Advanced Liver Cancer

October 17, 2017

Overall survival (OS) was improved when patients with advanced liver cancer took Cabometyx (cabozantinib), compared to those who were given placebo. All participants previously took Nexavar (sorafenib).

New Hodgkin Lymphoma Therapy in the Pipeline

October 02, 2017

Adcetris (brentuximab vedotin) was granted a breakthrough therapy designation by the Food and Drug Administration (FDA) for the frontline treatment of patients who have classical Hodgkin lymphoma

FDA Approves Jevtana for Prostate Cancer Subset

September 18, 2017

Jevtana (cabazitaxel) was granted approval by the Food and Drug Administration (FDA) for the treatment of men with metastatic castration-resistant prostate cancer who previously received a docetaxel-containing regimen.

Conmana Bests Chemotherapy in Progression-Free Survival for Lung Cancer

September 08, 2017

According to the results of a recent study conducted in China, patients with stage 3B/4 non-small cell lung cancer (NSCLC) saw a 3.3-month increase in median progression-free survival (PFS) when taking Conmana (icotinib) compared to those who were taking chemotherapy.

Keytruda Shows Benefit in Small Cell Lung Cancer

September 06, 2017

The immunotherapy agent Keytruda (pembrolizumab) had an overall response rate (ORR) of 33 percent in a recent trial including patients with extensive-stage small cell lung cancer (SCLC). Findings of the phase 1b KEYNOTE-028 trial were published in the Journal of Clinical Oncology.